Laureates’ affiliated institutions are listed, and the significance of each prize in accelerating scientific progress is highlighted.

Los Angeles hosts the gala where laureates will be celebrated, with a prize ceremony and related media assets available for press use.

The gala, described as the science world’s 'Oscars,' streams on YouTube on April 26, 2026, and is backed by founders Sergey Brin, Priscilla Chan, Mark Zuckerberg, Julia and Yuri Milner, and Anne Wojcicki.

The article traces the prize’s history, ongoing impact on science, and total disbursements to date.

In Life Sciences, FDA-approved gene replacement therapy for Leber congenital amaurosis, sickle cell disease and beta-thalassemia advances via fetal hemoglobin reactivation and CRISPR therapies, and the discovery of C9orf72 repeat expansion linking ALS and FTD are highlighted.

A new Vera Rubin New Frontiers Prize honors Carolina Figueiredo for geometric reformulations in particle physics, while three Maryam Mirzakhani New Frontiers Prizes go to Amanda Hirschi, Anna Skorobogatova, and Mingjia Zhang for early-career work in symplectic topology, geometric measure theory, and Shimura varieties.

Otis Chodosh earns the New Horizons in Mathematics Prize for differential geometry, while the team of Vesselin Dimitrov and Yunqing Tang receive the prize for advances in number theory and modular forms.

The ceremony showcases breakthroughs across life sciences, physics, and mathematics, with ongoing media access and sponsorship support.

The releases point to the prize founders and sponsors, and direct readers to the prize’s website for more information.

The Breakthrough Prize Foundation announces six 2026 laureates across Life Sciences, Fundamental Physics, and Mathematics, each prize worth $3 million and totaling $18.75 million for the year, pushing total lifetime awards above $340 million.

Stuart H. Orkin and Swee Lay Thein are recognized for enabling treatment of sickle cell disease and beta-thalassemia through fetal hemoglobin regulation, while Rosa Rademakers and Bryan Traynor are credited with identifying the C9orf72 repeat expansion as a common cause of ALS and FTD and related testing.